A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis.
Neurology
; 51(1): 239-45, 1998 Jul.
Article
em En
| MEDLINE
| ID: mdl-9674809
ABSTRACT
OBJECTIVE:
To compare the tolerability and efficacy of two doses of i.v. methylprednisolone in patients with secondary-progressive MS.METHODS:
I.v. methylprednisolone administered in high or low dose every other month for up to 2 years to 108 patients with secondary-progressive MS.RESULTS:
No significant difference in efficacy with the primary outcome, a comparison of the proportions of patients in each treatment group who experienced sustained progression of disability. A relative treatment effect was detected with the high-dose regimen as measured by the preplanned secondary analysis, a comparison of time to onset of sustained progression of disability. Drug-related adverse events were observed more frequently in high-dose recipients but serious drug-related adverse events were uncommon, and cessation of study drug was only required in one patient.CONCLUSION:
The results of the secondary analysis of this study suggest that a phase III trial of corticosteroids for secondary-progressive MS is warranted.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Metilprednisolona
/
Anti-Inflamatórios
/
Esclerose Múltipla
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Neurology
Ano de publicação:
1998
Tipo de documento:
Article
País de afiliação:
Estados Unidos